Inhibition of Growth of <I>Candida albicans</I> by a Lysozyme-chitosan Conjugate, LYZOX and its Combination with Decanoic Acid

Kageshima Hiroki, Hayama Kazumi, Takahashi Miki, Abe Miho, Yamada Tsuyoshi, Saito Akira, Hirano Shoichiro, Murakami Yoichi, Abe Shigeru

doi:10.3314/mmj.17-00005

Bibliographic Information

Other Title

リゾチーム-キトサン糖複合体LYZOX（リゾックス）およびデカン酸との組み合わせによるカンジダ増殖抑制効果
リゾチーム-キトサントウフクゴウタイ LYZOX(リゾックス)オヨビデカンサントノクミアワセニヨルカンジダゾウショクヨクセイコウカ

Search this article

Abstract

A lysozyme-chitosan conjugate preparation (LYZOX), produced from egg white lysozyme and chitosan by Maillard reaction, is a commercial product developed as a cosmetic ingredient or food additive. Effects of LYZOX on in vitro growth of Candida albicans were examined. C. albicans cells were treated with LYZOX for 3 hrs, and then washed and cultured for an additional 16 hrs in modified RPMI1640 medium. Mycelial growth of C. albicans was clearly inhibited by more than 100 μg/ml of LYZOX in a concentration-dependent manner. On the other hand, corresponding concentration of chitosan or lysozyme or their mixture only scarcely showed clear inhibitory effect. Similarly, anti-Candida activity of the combination of LYZOX and decanoic acid, a middle-chain fatty acid, was also examined. Inhibitory activity of this combination against mycelial growth of C. albicans was very potent and appeared synergistic, since fractionated inhibitory concentration (FIC) index for 70% growth inhibition was calculated to be 0.20. Oral application of this combination improved the symptoms of Candida-infected-tongue in an experimental murine candidiasis model. On the basis of these results, the possible application of LYZOX as a new functional product with anti-candida activity was discussed.

Journal

Medical Mycology Journal

Medical Mycology Journal 58 (3), J63-J69, 2017

The Japanese Society for Medical Mycology

Keywords

Details 詳細情報について

Export